Altavo concludes Series A for the development of its Artificial Voice

Altavo’s Artificial Voice is a medical device designed to help voiceless people, for example after laryngectomy or during mechanical ventilation, regain their own, natural sounding voice. The proprietary “silent speech” technology, which has been developed in collaboration with Technical University Dresden, is based on non-invasive radar sensing and the latest neural net architectures.

Investors in the current signficantly oversubscribed round are, in addition to the lead investor OCCIDENT from Munich, Novalis Biotech (Ghent, Belgium), Beteiligungsmanagement Thüringen, and others. In addition, almost all seed investors from the first financing round in December 2021 are participating with a follow-on investment, among them TGFS Technologiegründerfonds Sachsen, High-Tech Gründerfonds (HTGF), Saxonia Systems Holding and TUDAG TU Dresden AG.

The current Series A will finance company growth, product development, the pivotal clinical trial, and internationalization. Altavo’s technology not only promises to become a breakthrough in the rehabilitation of voiceless people, but also opens up entirely new opportunities in silent communication and human-machine interfaces.

“We are happy to have gained a strong European group of investors who share our vision: to help voiceless people regain their voice. With the financing now concluded, our clinical supporters, and our team, we see ourselves excellently positioned for the technical and clinical development ahead of us.” Rudolf von Bünau, CEO and co-founder, Altavo

“With our investment in Altavo we are banking on an experienced team with a compelling product vision. As a long-term oriented investor, our ambition is to support the team on their path into the market and to enable the realization of the company’s ambitious goals." Mirco Müller, Junior Investment Manager, OCCIDENT

“We were impressed with Altavo’s highly experienced and dedicated team and innovative, potentially disruptive technology. We look forward to supporting the company to bring this unique solution to voice-impaired individuals”. Jaroslav Belotserkovsky, Investment Manager, Novalis Biotech

“To us, Altavo, with its locations in Dresden and Jena, is a prime example of the innovation power of our central German region and of the successful collaboration between startups and universities. We are glad to be investing in a promising medtech company that benefits from the existing ecosystems in both locations and complements them.” Michael Thiele, Investment Manager, bm | t Beteiligungsmanagement Thüringen GmbH and Sören Schuster, CEO, TGFS Technologiegründerfonds Sachsen